The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s biosimilar interleukins market report forecasts the biosimilar interleukins market size to grow to $10.54 Billion by 2027, with a CAGR (compound annual growth rate) of more than 39%.

Learn More On The Biosimilar Interleukins Market Report 2023 – https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report

Biosimilar Interleukins Market Size Forecast

The global biosimilar interleukins market is expected to grow from $2.01 billion in 2022 to $2.8 billion in 2023 at a compound annual growth rate (CAGR) of 39.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biosimilar interleukins market is expected to grow from $10.54 billion in 2027 at a CAGR of 39.3%.

Key Biosimilar Interleukins Market Driver ­– Increase In The Prevalence Of Autoimmune Diseases

According to a Johns Hopkins University report published in 2021, autoimmune diseases affected approximately 3% of the population in the United States, or approximately 10 million people. Therefore, the increasing prevalence of autoimmune diseases is increasing the demand for the biosimilar interleukins market and is expected to drive the growth of the market.

Request for A Sample Of The Global Biosimilar Interleukins Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3433&type=smp

Biosimilar Interleukins Market Segment

1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6

2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes

Biosimilar Interleukins Market Major Players and Strategies

Major players in the biosimilar interleukins market are MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech, and Sunshine Guojian Pharmaceutical.

In January 2020, Sanofi, a France-based pharmaceutical company, acquired Synthorx, Inc. for $2.5 billion. This acquisition enhances Sanofi’s position as an emerging leader in the areas of oncology and immunology. Synthorx, Inc. is a US-based biotechnology company focused on developing interleukins for people suffering from cancer and autoimmune disorders.

The Biosimilar Interleukins Global Market Report 2023 covers regional data on biosimilar interleukins market size, biosimilar interleukins market trends and drivers, opportunities, strategies, and biosimilar interleukins market competitor analysis. The countries covered in the biosimilar interleukins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Biosimilar interleukins is defined as a biosimilar produced by the body’s leukocytes (white blood cells). Immune reactions are controlled by interleukins. Laboratory-produced interleukins are used as biological response modifiers to strengthen the immune system in cancer treatment.

View More Reports Related To The Biosimilar Interleukins Market –

Biosimilars Global Market Report 2023

Biosimilar Monoclonal Antibodies Global Market Report 2023

Trastuzumab Biosimilars Global Market Report 2023

Email us at [email protected]

Call us at:

Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708

Follow us on:

LinkedIn: https://bit.ly/3WzV8lZ

YouTube: https://bit.ly/3jiemhz

Global Market Model: https://bit.ly/3Was30B